Effect of Finerenone in IgA Nephropathy

Sponsor
Zhejiang University
Study ID
NCT06580288
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    10mg or 20mg
  • Placebo — DRUG
    10mg or 20mg

Study Details

The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.

Key Dates

Start date
Oct 8, 2024
Status verified
Aug 2024
Primary completion
Jun 8, 2026
Completion
Oct 8, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Finerenone
  • Placebo Comparator: placebo

Primary Outcome Measure

change in uACR between the two groups [ Time Frame: at 12months ]

Central Contacts

Related Studies